We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.

FOR PREVIEW ONLY (Print)

Patrick D. Lyden, MD

Carmen and Louis Warschaw Chair in Neurology

Chair, Department of Neurology

Director, Cedars-Sinai Stroke Center

Advanced Health Sciences Pavilion, A6600
127 S. San Vicente Blvd.
Los Angeles, CA 90048

Phone:

310-423-7900

Fax:

310-423-0777

Parking Instructions:

Closest parking is in Lot 4 on Sherbourne Drive.

Patrick D. Lyden, MD

Carmen and Louis Warschaw Chair in Neurology

Chair, Department of Neurology

Director, Cedars-Sinai Stroke Center

  • Neurology

ALS (Lou Gehrig's Disease)

Alzheimer's Disease

Amyloidosis

Bell's Palsy

Brain Aneurysms

Brain Hemorrhage

Carotid Artery Diseases

Carotid Surgery / Surgeries

Carpal Tunnel Release Surgery / Surgeries

Carpal Tunnel Syndrome

Cervical Myelopathy

Concussions

Dementia

Essential Tremors

Lumbar Puncture

Meningitis

Moya Moya Disease

Multiple Sclerosis

Musculoskeletal Disorders

Neuromuscular Disorders

Parkinson's Disease

Postherpetic Neuralgia

Sarcoidosis

Seizure Disorders (Epilepsy)

Spontaneous Intracranial Hypotension

Stroke (Cerebrovascular Accident) - CVA

TIC Disorders

Thoracic Myelopathy

Trigeminal Neuralgia

Vertigo

Vestibular Dysfunction

Show moreShow less

The research of Patrick D. Lyden, MD, focuses on translational stroke research. One theme involves understanding the role of thrombin in mediating cytotoxicity during ischemia. In collaboration with Roger Tsien at University of California, San Diego and other colleagues, Lyden's research has shown that during a stroke, thrombin enters the brain, adheres to neurons, and kills them via the protease activated receptor (PAR-1). His research has also shown that thrombin inhibitors block this cytotoxicity and ameliorate the behavioral and histological effects of stroke. Recently, Lyden and his colleagues have shown that thrombin inhibitor Argatroban powerfully protects the brain when delayed as late as three hours after stroke. Future studies are aimed at understanding the mechanism by which thrombin enters brain and whether thrombin plays any other roles, such as pre-conditioning. A second theme involves treating stroke with hypothermia. Lyden and his colleagues propose to address critical questions about cooling target-depth, duration, and delay-time window, as well as develop new tools for translational studies in this field. He aims to determine the relationship among target-depth, duration, and delay, and to develop new models for conducting further research into therapeutic hypothermia, considered the most potent putative neuroprotectant available.

  • Internship: Mercy Hospital and Medical Center, 1982
  • Residency: University of California, San Diego School of Medicine, 1985
  • Fellowship: University of California, San Diego School of Medicine, 1987
  • Associate Editor: The International Journal of Stroke, Current
  • Editorial Board: Stroke, Current
  • Editorial Board: Therapeutic Hypothermia and Temperature Management, Current
  • Peer Reviewer: Science Translational Medicine, Current
  • Peer Reviewer: Lancet, Current
  • Best Doctors in America, 2009-present
  • Carmen and Louis Warschaw Chair in Neurology, 2009
  • Best Doctors in San Diego, 2005
  • Elected Member, American Neurological Association, 2003
  • Heart of Gold Honoree, American Heart Association San Diego Affiliate, 2002
  • Society for Neuroscience, 1999
  • American Society of Neuroimaging, 1999
  • Elected Fellow, American Heart Association, Stroke Council, 1998
  • Elected Fellow, American Academy of Neurology, 1998
  • American Heart Association, 1992
  • California Medical Association, 1991
  • American Medical Association, 1990
  • American Neurological Association, 1988
  • Stroke Council, American Stroke Association, 1988
  • American Academy of Neurology, 1987

Show moreShow less

  • Chen B, Friedman B, Whitney MA, Winkle JA, Lei IF, Olson ES, Cheng Q, Pereira B, Zhao L, Tsien RY, Lyden PD. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci. 2012;32(22):7622-7631.
  • Chen B, Van Winkle JA, Lyden PD, Brown JH, Purcell NH. PHLPP1 gene deletion protects the brain from ischemic injury. J Cereb Blood Flow Metab. 2012;33(2):196-204.
  • Lyden P, Pereira B, Chen B, Zhao L, Lamb J, Lei IF, Rajput P. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke. 2014;45(3):896-899.
  • Lyden PD. Hemorrhagic transformation during thrombolytic therapy and reperfusion: effects of age, blood pressure, and matrix metalloproteinases. Journal of stroke and cerebrovascular diseases. J Stroke Cerebrovasc Dis. 2013;22(4):532-538.
  • Van Winkle JA, Chen B, Lei IF, Pereira B, Rajput PS, Lyden PD. Concurrent middle cerebral artery occlusion and intra-arterial drug infusion via ipsilateral common carotid artery catheter in the rat. J Neurosci Methods. 2012;213(1):63-69.
  • Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke. 2013;44(12):3529-3536.
  • Rajput PS, Lyden PD, Chen B, Lamb J, Pereira B, Lamb A, Zhao L, Lei IF, Bai J. Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models. Neuroscience. 2014;281C:229-240.

Show moreShow less

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Patrick D. Lyden, MD